CGN-004

CGN-004 is a preclinical drug candidate being developed by CitraGen Pharmaceuticals for the treatment of migraine. CitraGen Pharmaceuticals focuses on the development of specialty pharmaceuticals, specifically utilizing the 505(b)(2) regulatory pathway and complex generic strategies. This approach typically involves creating new formulations, dosages, or delivery systems for previously approved active pharmaceutical ingredients to improve efficacy, safety, or patient compliance. While the specific active ingredient and molecular target of CGN-004 have not been publicly disclosed, it is part of a series of early-stage assets in CitraGen's pipeline targeting migraine and pain management.